Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation — Steven Deitelzweig (2024) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
Shared by
Professor Gregory Lip
University of Liverpool
Clinical Impact of Switching or Continuation of Apixaban or Rivaroxaban among Patients with Non-Valvular Atrial Fibrillation
Article
2024
en
Authors
+7 more
SD
Steven Deitelzweig
AK
Amiee Kang
JJ
Jenny Jiang
Abstract
1 min read
These findings may aid physicians and patients in making informed decisions when considering a switch between apixaban and rivaroxaban.
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2025
Plain language summary of the direct oral anticoagulant switch study: effect of switching or continuing apixaban or rivaroxaban among people with non-valvular atrial fibrillation
Steven Deitelzweig
,
Jenny Jiang
,
Dong Cheng
,
Professor Gregory Lip
Article
2018
Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban
Ping G. Tepper
,
Jack Mardekian
,
Cristina Masseria
,
Hemant Phatak
,
Shital Kamble
,
Younos Abdulsattar
,
William Petkun
,
Professor Gregory Lip
Article
2016
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin
Allison Keshishian
,
Shital Kamble
,
Xianying Pan
,
Jack Mardekian
,
Ruslan Horblyuk
,
Melissa Hamilton
,
Professor Gregory Lip
Article
2016
Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States
Professor Gregory Lip
,
Xianying Pan
,
Shital Kamble
,
Hugh Kawabata
,
Jack Mardekian
,
Cristina Masseria
,
Amanda Bruno
,
Hemant Phatak
Article
2018
Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban
Professor Gregory Lip
,
Xianying Pan
,
Shital Kamble
,
Hugh Kawabata
,
Jack Mardekian
,
Cristina Masseria
,
Hemant Phatak
Discussion(0)
No comments yet. Be the first to comment.